Health data is centre stage in many of the call topics for research and development projects and initiatives sponsored by industry and national eHealth and research bodies.
There is a burning need to collect, use and reuse health data for understanding disease trajectories, identifying trends, predicting evolutions, taking the right care planning decisions and accelerating research.
State-of-the-art innovation
i~HD plays a strong role in national and international R&D projects and European-wide collaborative initiatives.
We highly value participating in these projects and initiatives because it allows us to keep connected with the state of the art in innovative aspects of health care and clinical research.
The projects provide us with opportunities to put our services and expertise into practical scenarios, to learn, to improve and to expand our portfolio of health data solutions.
We are often invited to be a partner, providing expertise in many fields:
- data protection and GDPR compliance
- data sharing agreements
- anonymisation and pseudonymisation
- data quality benchmarking
- research platform quality assessment
- business modelling and sustainability
- dissemination and multi-stakeholder engagement
Research Projects
We are a partner in a diverse range of European Commission sponsored projects, in Horizon 2020, the Innovative Medicines Initiative and EIT Health.
AFFIRMO: a multi-centre informatics driven clinical study to validate the effectiveness of a patient-centred, stratified care pathway for older patients with multimorbidity that includes atrial fibrillation
Developing algorithms for the early detection of deterioration in advanced long-term conditions, well-coordinated care planning and integrated care to enhance quality of life
A scalable and sustainable medical image platform utilising Artificial Intelligence (AI) to improve diagnostic accuracy, and enabling there future development of AI algorithms
Large-scale generation of real world evidence for medicines safety in pregnancy and lactation, seeking to establish a sustainable Real World Evidence (RWE) ecosystem and stakeholder acceptance of RWE
Scaling up paediatric clinical trials across Europe, with a small part of the work plan for methodologies and tools including data management, standards and use of real world data
DATA QUALITY CAMPUS
Starting in March 2021, developing a virtual educational campus focusing on EHR data quality and related topics, especially for the reuse of EHRs for research
Reusing hospital EHR data within clinical trials by mapping and transferring data to Electronic Data Capture (clinical trial) systems, now in annual industry-supported project cycles
Developing a generic specification, methodologies, tools, governance and business models for Integrated Research Platforms (IRPs) = multi-company multi-drug trials. 4 disease area pilots
Developing scalable and secure distributed analysis platforms and tools to conduct research using a network of European registries in autoimmune vasculitis
Developing trustable and explainable Artificial Intelligence for personalised decision making in patients with haematological conditions, combining clinical and genomics data from a European network
Improving patient acceptance, adherence and benefit from medicines by providing them with better and personalised information about their medicines and other health status monitoring
Conduct novel PhD research, using linked health and life science data, for patients with autoimmune vasculitis as an example rare condition
Promoting early identification and improving outcomes for patients with psoriatic arthritis
Establishing sustainable Health Outcomes Observatories at national and EU levels to collect, use and reuse outcomes to improve patient care and research. 3 diseases and 4 country pilots
Establishing sustainable Health Outcomes Observatories at national and EU levels to collect, use and reuse outcomes to improve patient care and research. 3 diseases and 4 country pilots
Ended in June 2019. Coordination and supported efforts towards an interoperable international patient summary
Supporting the adoption of ISO IDMP (ID of Medicinal Products) standards across Europe, supporting safer cross-border ePrescription, eDispensing and pharmacovigilance
- We are currently in projects making trustworthy use of hospital electronic health record information to improve the efficiency and quality of clinical trials, projects that are scaling up the generation of real-world evidence by networking multiple electronic health records and registries and other data sources.
- We are involved in research projects focusing on specific patient populations, such as women in pregnancy, and patients with rare diseases.
- We are working on societal challenges of improving healthcare, for example in patients with multiple long-term conditions, the collection and sharing of health outcomes data across Europe and the creation of a knowledge hub on mobile health programmes.
- We have two projects taking a deep dive into medicines information, one promoting the adoption of an international standard for the identification of medicinal products, and one enabling better medicines information to support patient empowerment and decision making.
Our experience in European projects
Via our founding members, i~HD can boast
i~HD expertise in R&D is built on a long history of participating in (EU-funded) projects thanks to its founding members EuroRec and RAMIT (over 100 R&D projects), strengthened by our large international community of experts. We have a lot of successful proposal writing and project co-ordination expertise.
Besides performing and supporting research, i~HD is able to assist research consortia in building sustainable models and solutions. i~HD is itself a successful sustainable outcome of EU R&D projects in 2016. Being a neutral European wide non-for-profit association, i~HD can disseminate project progress and its final results to multiple stakeholders active in the domain of health data.
Interested? Get in touch!
If you are planning a new project proposal, you are welcome to discuss the ways in which we could contribute with
Dipak Kalra.